acebutolol and Graft-Versus-Host Disease

acebutolol has been researched along with Graft-Versus-Host Disease in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Baron, F; Beguin, Y; De Becker, A; Emonds, MP; Graux, C; Kerre, T; Lewalle, P; Maertens, J; Ory, A; Seidel, L; Theunissen, K; Van Gelder, M; Willems, E; Zachée, P	1

Trials

1 trial(s) available for acebutolol and Graft-Versus-Host Disease

Article	Year
Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society. Journal of hematology & oncology, 2015, Feb-06, Volume: 8 Topics: Adult; Aged; Allografts; Antilymphocyte Serum; Antineoplastic Agents; Chemoradiotherapy; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Maltose; Middle Aged; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation	2015

Article

Year

Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society.

Journal of hematology & oncology, 2015, Feb-06, Volume: 8

Topics: Adult; Aged; Allografts; Antilymphocyte Serum; Antineoplastic Agents; Chemoradiotherapy; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Maltose; Middle Aged; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2015